Research Roundup: Engineered Nanoparticles and New Potential Standards of Care
Positive results from a phase 3 trial of Astellas Pharmaceuticals’ zolbetuximab and modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) “may represent a... Read More
Research Roundup: Mushroom Consumption and Lowered Risk
In a clinical trial, patients with gastric cancer who received low-dose olanzapine during chemotherapy experienced improved appetite and weight gain over those... Read More
CISCRP Invites Patients and Caregivers to Participate in Gastric Cancer Focus Group
The Center for Information & Study on Clinical Research Participation (CISCRP) is looking for patients and their care partners who feel comfortable... Read More
Gastric Cancer Registry Completes Major Data Expansion
In 2021, the Gastric Cancer Foundation granted $257,856 to fund an expansion of the Gastric Cancer Registry (GCR) at Stanford University, which... Read More
Dana-Farber Researcher Wins GCF Grant to Probe PARP Inhibition in Gastric Cancer
Could new technology help identify a new role in gastric cancer for a drug that’s been used for the past eight years... Read More
Foundation Awards Two $100,000 Grants to Advance Gastric Cancer Research
The Gastric Cancer Foundation is committed to addressing a key funding gap in research: Very little funding is available to early- and... Read More
Foundation Awards New Grants to Researchers Pursuing Novel Approaches in Gastric Cancer
The biggest challenge facing researchers who have exciting but unproven ideas for fighting gastric cancer is raising the funds they need to... Read More
Nivolumab/Paclitaxel Combo Shows Antitumor Activity in EBV-Related, MSI-H, PD-L1+ Advanced Gastric Cancer
Opdivo combined with paclitaxel showed anti-tumor activity in a phase 1/2 study of gastric cancer patients with a variety of tumor markers,... Read More
Amgen’s Investigational Bemarituzumab Receives Breakthrough Therapy Designation
The FDA granted breakthrough therapy designation to an experimental drug from Amgen for patients with FGFR2b over expressing and HER2-negative gastric cancer.
Investigational Anti-PD-1 Agent Shows Potential for Treatment of Unresectable or Metastatic MSI-H/dMMR Solid Tumors
The novel checkpoint inhibitor HLX10 showed positive safety and efficacy in a phase 2 clinical trial in patients with microsatellite instability-high or... Read More
